No, you do not need to repeat laboratory testing for a Medicare Annual Wellness Visit if labs were already performed when establishing care.
The Medicare Annual Wellness Visit (AWV) is fundamentally a preventive care visit focused on health risk assessment, screening recommendations, and care planning—not a routine laboratory testing encounter. In fact, performing routine laboratory tests during AWVs represents low-value care that can trigger unnecessary care cascades.
Key Evidence Against Routine Lab Testing at AWVs
Research demonstrates that routine testing during Medicare AWVs is considered low-value care 1. Among 75,275 healthy Medicare beneficiaries receiving AWVs, 18.6% received at least one low-value test (ECG, urinalysis, or thyroid testing), which subsequently triggered care cascades with modest but notable costs—approximately $9.62 per beneficiary for ECG cascades and $7.46 for urinalysis cascades 1. These tests were performed in healthy adults without relevant prior conditions or symptoms, making them particularly wasteful.
What the AWV Actually Requires
The Medicare AWV is designed to:
- Establish or update a personalized prevention plan
- Conduct health risk assessments
- Review current providers and medications
- Measure height, weight, blood pressure, and BMI
- Provide screening recommendations based on age and risk factors
Laboratory testing is only indicated when clinically appropriate based on the health risk assessment findings, not as a routine component of the visit 1.
Clinical Decision-Making Algorithm
If labs were done at the initial "establish care" visit:
- Review those recent results during the AWV
- Only order new labs if:
- Sufficient time has passed based on condition-specific guidelines (e.g., diabetes screening every 3 years for average-risk patients 2)
- New symptoms or conditions emerge during the AWV
- Chronic disease monitoring is due based on established intervals
- Specific preventive screening is indicated by age/risk factors
Common pitfall to avoid: Do not reflexively order labs simply because it's an annual visit. This represents the type of repetitive testing that wastes resources—unnecessary repeat testing can constitute 16.78% of laboratory workload with costs exceeding $132,000 annually in single facilities 3.
Financial and Quality Considerations
Pharmacist-led AWVs have demonstrated comparable or superior quality metric satisfaction (57.1% of HRSA/UDS quality metrics satisfied) without routine laboratory testing 4. The focus should be on screening recommendations and care coordination rather than reflexive test ordering 5.
The evidence is clear: resist the urge to order routine labs during AWVs when recent results are available. Instead, use the visit to review existing data, update preventive care plans, and order targeted testing only when clinically indicated by new findings or appropriate time intervals for chronic disease monitoring.